Taiho Oncology and Cullinan Therapeutics said their Phase 3 trial of zipalertinib plus chemotherapy in frontline EGFR exon 20 insertion–positive lung cancer met pre-planned thresholds for unblinding, setting up a registrational matchup with established EGFR competitors. The companies framed the results as statistically significant and clinically meaningful on progression-free survival, with additional timing cues tied to expected regulatory decisions. The program’s progression highlights how the EGFR exon 20 insertion niche continues to attract late-stage investments and rapid competitive positioning, particularly as existing branded EGFR therapies defend share while next-gen agents seek earlier-line dominance.